
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript
Loading news...

Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript

KIRKLAND, Wash., March 17, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the third quarter fiscal 2026, which ended January 31, 2026.

KIRKLAND, Wash., March 03, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced that it will report third quarter fiscal 2026 financial results on Tuesday, March 17. Management will host a corresponding conference call at 4:30 p.m. Eastern Time.

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the firm's stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $22.80, for a total value of $342,000.00. Following the sale, the insider owned 394,786 shares in the company, valued

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,413,847 shares, an increase of 21.5% from the December 15th total of 1,986,266 shares. Currently, 4.3% of the shares of the company

Kestra teams up with Biobeat in an exclusive deal, investing $5M to add continuous blood pressure monitoring to the ASSURE WCD during cardiac recovery.

Kestra Medical Technologies, Ltd. (KMTS) Presents at 44th Annual J.P.

KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) was down 6.1% during trading on Friday. The stock traded as low as $24.89 and last traded at $24.89. Approximately 49,243 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 289,819 shares. The stock had previously closed at

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $26.59, for a total value of $398,850.00. Following the transaction, the insider directly owned 409,786 shares in the company, valued

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) insider Traci Umberger sold 10,500 shares of the business's stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $26.69, for a total value of $280,245.00. Following the sale, the insider directly owned 136,633 shares in the

Shares of Kestra Medical Technologies, Ltd. (NASDAQ: KMTS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy

KIRKLAND, Wash., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 at 2:15 p.m. Pacific Time.

Kestra Medical Technologies, Ltd. (KMTS) Q2 2026 Earnings Call Transcript

KIRKLAND, Wash., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the second quarter fiscal 2026, which ended October 31, 2025.

KIRKLAND, Wash., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.

KIRKLAND, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced an underwritten public offering of 5,500,000 common shares. Kestra is offering these shares pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (“SEC”). Kestra also intends to grant the underwriters a 30-day option to purchase up to an additional 825,000 common shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed or as to the actual size or terms of the offering. Kestra intends to use the proceeds to support sales and marketing activities, to drive ongoing commercialization, to further fund our research and development and clinical studies and for working capital and general corporate purposes. All of the common shares are being offered by Kestra.

KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported preliminary financial results for the second quarter fiscal 2026 ended October 31, 2025.

KIRKLAND, Wash., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS), presented as a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans. ACE-PAS, the largest prospective real-world study of wearable defibrillators to date, confirmed the strong safety and effectiveness of the ASSURE WCD in clinical practice.